ABSTRACT
The aim of the present study was to clarify the morphologic characteristics of time-intensity curves (TICs) that are useful for distinguishing benign from malignant lesions. One hundred three patients with breast lesions underwent dynamic breast MRI. The areas under the receiver operating characteristic (ROC) curves (AUC) from every component of TIC were compared between benign and malignant disease. As a result, angle of cross line between 1 and 4 min is more useful than rapid enhancement for distinguishing benign from malignant lesions.
Subject(s)
Algorithms , Breast Neoplasms/pathology , Breast/pathology , Image Interpretation, Computer-Assisted/methods , Magnetic Resonance Imaging/methods , Adult , Aged , Female , Humans , Image Enhancement/methods , Middle Aged , ROC Curve , Reproducibility of Results , Sensitivity and Specificity , Young AdultABSTRACT
UNLABELLED: The anti-tumor effects and tissue distribution of carboplatin (CBDCA) incorporated into hydroxyapatite (HAP) particles was studied. MATERIALS AND METHODS: Seven days after the intraperitoneal (i.p.) implantation of AH130 tumor cells into Donryu rats, the animals were randomized into four groups: group I was treated with saline i.p.; Group II, with CBDCA i.v.; group III with CBDCA i.p.; and group IV with HAP-CBDCA i.p. RESULTS: The survival rate of group IV was better than that of the other groups (p < 0.05). The area under the ascitic platinum concentration-time curve and tissue concentrations of platinum in the omentum after 24 hours of treatment were higher in group IV than in groups II or III (p < 0.05). The platinum concentrations in the kidneys of group IV were lower than in group III (p < 0.05). CONCLUSION: The HAP-CBDCA combination enhances the anti-tumor effects of the drug and reduces the nephrotoxicity in rats with peritoneal carcinomatosis.
Subject(s)
Antineoplastic Agents/therapeutic use , Carboplatin/therapeutic use , Peritoneal Neoplasms/drug therapy , Animals , Antineoplastic Agents/pharmacokinetics , Area Under Curve , Carboplatin/pharmacokinetics , Male , RatsABSTRACT
A 66-year-old man complained of epigastralgia and a close examination was done. A type 3 gastric carcinoma was found. The tumor invading the pancreas and swelling lymphnodes around the stomach were confirmed according to abdominal CT. We considered it difficult to resect the tumor completely, and so we used combined chemotherapy of TS-1 plus CDDP. TS-1 was taken at 120 mg/day for 28 days followed by 14 days rest. CDDP was injected at 140 mg on day 8. Because the tumor in the stomach changed to scar and swelling lymphnodes diminished after two courses of therapy, total gastrectomy was done. After operation, combined chemotherapy of LV and 5-FU resulted in no recurrence to date. Although combined chemotherapy of TS-1 plus CDDP is effective for advanced gastric carcinoma, the number of days TS-1 is taken and the duration of the preoperative chemotherapy must be investigated in forthcoming study.
Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gastrectomy , Stomach Neoplasms/drug therapy , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Cisplatin/administration & dosage , Combined Modality Therapy , Drug Administration Schedule , Drug Combinations , Gastroscopy , Humans , Lymph Node Excision , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Neoplasm Invasiveness , Oxonic Acid/administration & dosage , Pancreatic Neoplasms/pathology , Pyridines/administration & dosage , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Tegafur/administration & dosageABSTRACT
Radiotherapy is now commonly employed in patients with inoperable esophageal cancer which invased neighbor organs directly. A rare, but often fatal complication of radiotherapy is perforation with mediastinal abscess. We successfully treated a 65-year-old male patient who developed an esophageal cancer with trans-esophageal drainage and irrigation. This technique may also be useful in the treatment of patients with anastomotic leaks after esophagectomy or idiopathic esophageal rupture.
